-

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2026 annual meeting of shareholders (the “Annual Meeting”) held on May 20, 2026. The detailed results of the vote for the election of directors are set out below:

Name

For

Against

Broker Non-Votes

Eduardo Alfonso, M.D.

331,573,622

4,244,069

11,452,072

Nathalie Bernier

331,522,655

4,295,036

11,452,072

Steven H. Collis

331,575,559

4,242,132

11,452,072

Sarah B. Kavanagh

331,548,740

4,268,951

11,452,072

Karen L. Ling

331,533,402

4,284,289

11,452,072

John A. Paulson

331,537,843

4,279,848

11,452,072

Russel C. Robertson

331,561,696

4,255,995

11,452,072

Thomas W. Ross, Sr.

331,556,884

4,260,807

11,452,072

Brenton L. Saunders

331,476,725

4,340,966

11,452,072

Andrew C. von Eschenbach, M.D.

331,499,049

4,318,642

11,452,072

At the Annual Meeting, shareholders also approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers and appointed PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm until the close of the Company's 2027 annual meeting of shareholders.

The final vote tabulation on all matters voted on at the Annual Meeting will be filed with the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company’s website at www.bausch.com.

About Bausch + Lomb

Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

© 2026 Bausch + Lomb

Contacts

Media:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735

Bausch + Lomb Corporation

NYSE:BLCO

Release Versions

Contacts

Media:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735

More News From Bausch + Lomb Corporation

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocular lenses (IOLs). The study, published in the journal Ophthalmology and Therapy, found that these enhanced monofocal lenses delivered both good distance and functional intermediate vision, thus meeting...

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlighting a significant awareness gap around dry eye and its association with perimenopause and menopause. The survey found that dry eye remains one of the least recognized symptoms experienced during these stages of life. According to the survey, only 14% of peri-, menopausal and p...

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results. “Helping people see better to live better starts with tackling the challenges patients still face every day,” said Bausch + Lomb CEO Brent Saunders. “These results suppor...
Back to Newsroom